返回
I
Istituto Di Ricerche Farmacologiche Mario Negri Irccs
学者数50
论文数17
被引数338
关联论文 (2338)
发表时间
Rationale and design of the AUSTRAL trial: An open-label, multicenter, phase II study evaluating radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses and/or oligometastases after the PACIFIC regimen.AUSTRAL试验的原理与设计:一项开放标签、多中心、II期研究,旨在评估在完成PACIFIC方案治疗后出现胸腔内复发和/或寡转移的III期NSCLC患者中,采用放疗后序贯度鲁瓦木单抗(MEDI4736)和塞拉拉塞替(AZD6738)的治疗效果。
Clinical Lung Cancer
IF3.3

